The specifics of CpG islets methylation of some genes of peripheral blood T-lymphocytes in breast cancer patients before and after treatment

Introduction. The growth of primary breast tumor morbidity in the last ten years and increased number of patients with disseminated breast cancer in the Republic of Kazakhstan require the search for methods of early diagnosis of malignant tumors. Determination of breast cancer markers in epigenetic studies allows to use them as diagnostic signs of the presence of malignant tumor and as predictors of treatment effectiveness in patients with this pathology.

Aim. To perform  a search for therapeutic and prognostic breast cancer markers.

Materials and methods. The study included samples of biological material (peripheral blood) of 50 deemed healthy individuals and 103 patients with locally advanced and disseminated breast cancer receiving special therapy. The following methods were used: blood collection, DNA extraction, creation of DNA methylation profiles, sequencing, statistical data analysis.

Results. The results of search for epigenetic mutations in peripheral blood of patients with breast cancer showed their role as specific diagnostic, therapeutic and prognostic markers with specificity 0.91 % and sensitivity 0.94 %. The hypothesis on therapeutic  significance of identified earlier diagnostic markers in patients  with breast cancer, namely hypermethylation of CpG islands associated with genes JAM3, C17orf64,  MSC, C7orf51  and CpG island associated with intragene part of chromosome 5 (chr5: 77,208,034–77,329,434) was tested and confirmed.

Conclusion. A correlation between DNA methylation characteristics and disease progression during treatment was shown. The study results can be used in clinical practice: epigenetic markers, such as methylation in the CpG islets associated with the JAM3, C17orf64, MSC, C7orf51 genes, and in the CpG islet associated with the intragenic site of chromosome 5 (chr5: 77,208,034–77,329,434) can be used as prognostic markers and therapeutic predictors of breast cancer.

1. Kaidarova D.R., Shatkovskaya O.V., Abdrakhmanova A.Z. et al. Breast cancer epidemiology in Kazakhstan (2014–2018). Onkologiya i radiologiya Kazakhstana = Oncology and Radiology of Kazakhstan 2019;54(4):4–8. (In Russ.).

2. Shatkovskaya O.V., Kaidarova D.R., Dushimova Z.D. et al. Trends in incidence, molecular diagnostics, and treatment of patients with breast cancer in Kazakhstan, 2014–2019. Onkologiya i radiologiya Kazakhstana = Oncology and Radiology of Kazakhstan 2021;62(4):16–23. DOI: 10.52532/2521-6414-2021-4-62-16-23

3. Szyf M. DNA methylation signatures for breast cancer classification and prognosis. Genome Med 2012;30(4):26. DOI: 10.1186/gm325

4. Bjaanæs M.M., Fleischer T., Halvorsen A.R. et al. Genome-wide DNA methylation analyses in lung adenocarcinomas: association with EGFR, KRAS and TP53 mutation status, gene expression, and prognosis. Mol Oncol 2016;10:330–43. DOI: 10.1016/j.molonc.2015.10.021

5. Swann J.B., Smyth M.J. Immune surveillance of tumors. J Clin Invest 2007;117(5):1137–46. DOI: 10.1172/JCI31405

6. Goncharova T.G., Kaidarova D.R., Kadyrbaeva R.E. et al. Development of a method for early diagnosis of lung cancer based on methylation of blood mononuclear fraction cells. Onkologiya i radiologiya Kazakhstana = Oncology and Radiology of Kazakhstan 2020;3(57):13–20. (In Russ.). DOI: 10.52532/2521-6414-2020-3-57-13-20

7. Guerrero-Preston R., Hadar T., Ostrow K.L. et al. Differential promoter methylation of kinesin family member 1a in plasma is associated with breast cancer and DNA repair capacity. Oncol Rep 2014;32(2):505–12.

8. Kanwal R., Gupta S. Epigenetic modifications in cancer. Clin Genet 2012; 81(4):303–11. DOI: 10.1111/j.1399-0004.2011.01809.x

9. Cheishvili D., Christiansen S., Stochinsky R. et al. DNA methylation controls unmethylated transcription start sites in the genome in trans. Epigenomics 2017;9(5):611–33. DOI: 10.2217/epi-2016-0141

10. Cheishvili D., Stefanska B., Yi C. et al. A common promoter hypomethylation signature in invasive breast, liver and prostate cancer cell lines reveals novel targets involved in cancer invasiveness. Oncotarget 2015;6(32):33253–68. DOI: 10.18632/oncotarget.5291

11. Midthun D.E. Early detection of lung cancer. F1000Res 2016;25(5): F1000 Faculty Rev-739. DOI: 10.12688/f1000research.7313.1

12. Drake R.R., Cazares L.H., Jones E.E. et al. Challenges to developing proteomic-based breast cancer diagnostics. OMICS 2011;15(5):251–9. DOI: 10.1089/omi.2010.0120

13. Birse C.E., Lagier R.J., FitzHugh W. et al. Blood-based lung cancer biomarkers identified through proteomic discovery in cancer tissues, cell lines and conditioned medium. Clin Proteomics 2015;12(1):18. DOI: 10.1186/s12014-015-9090-9

14. Yang R., Pfütze K., Zucknick M. et al. DNA methylation array analyses identified breast cancer associated HYAL2 methylation in peripheral blood. Int J Cancer 2015;136(8):1845–55. DOI: 10.1002/ijc.29205

15. Kuchiba A., Iwasaki M., Ono H. et al. Global methylation levels in peripheral blood leukocyte DNA by LUMA and breast cancer: a case–control study in Japanese women. Br J Cancer 2014;110(11):2765–71. DOI: 10.1038/bjc.2014.223

16. Parashar S., Cheishvili D., Mahmood N. et al. DNA methylation signatures of breast cancer in peripheral T-cells. BMC Cancer 2018;18(1):574. DOI: 10.1186/s12885-018-4482-7

17. Goncharova T.G., Kaidarova D.R., Omarbayeva N.A. et al. Epigenetic markers-based breast cancer early detection method development. Onkologiya i radiologiya Kazakhstana = Oncology and Radiology of Kazakhstan 2020;58(4):29–35. (In Russ.). DOI: 10.52532/2521-6414-2020-4-58-29-35

18. Kloten V., Schlensog M., Magnus L. et al. Epigenetic loss of putative tumor suppressor SFRP3 correlates with poor prognosis of lung adenocarcinoma patients. J Epigenetics 2018;13(3):217–27. DOI: 10.1080/15592294.2016.1229730

19. Brennan K., Flanagan J.M. Is there a link between genome-wide hypomethylation in blood and cancer risk? Cancer Prev Res 2012;5(12):1345–57. DOI: 10.1158/1940-6207.CAPR-12-0316

20. Solopova A.G., Blinov D.V., Demyanov S.V. et al. Epigenetic aspects in rehabilitation of female cancer patients. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya = Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology 2022;15(2): 294–303. (In Russ.). DOI: 10.17749/2070-4909/farmakoekonomika.2022.141

21. LuoY.H., Luo L., Wampfler J.A. et al. 5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study. Lancet Oncol 2019;20(8):1098–108. DOI: 10.1016/S1470-2045(19)30329-8